Tag: Health Care

Displaying 581 - 600 of 802 results.

A final consent order permits Pfizer Inc.'s acquisition of Phamacia Corporation while requiring the divestiture of various products including extended release drugs used in the treatment of an overactive bladder; hormone replacement therapies; erectile dysfunction; canine arthritis;...
Pfizer Inc., and Pharmacia Corporation will divest pharmaceutical products in nine separate product markets to different third parties to settle Federal Trade Commission charges that the merger of Pharmacia and Pfizer likely would have anticompetitive effects in those product markets and violate...
The Federal Trade Commission and Department of Justice today released a detailed schedule listing specific witnesses for the sessions of their joint hearings on health care and competition law and policy to be held April 23 - 25 and May 7 - 8, 2003. These hearings will be held at the FTC...
The third session of the Federal Trade Commission/Department of Justice joint hearings on health care and competition law and policy will begin on Wednesday, April 9 at 2:00 p.m. The agenda for the session is available at http://www.ftc.gov/ogc/healthcarehearings/ and athttp://www.usdoj.gov/atr/...
United States Attorney Michael J. Sullivan, Assistant Attorney General Robert D. McCallum, Jr., and Federal Trade Commission Bureau of Competition Director Joe Simons announced today that a federal judge has fined Boston Scientific Corporation (BSC) more than $7 million for violating an FTC order...
  The Federal Trade Commission and the Department of Justice today released a detailed schedule for the sessions of their joint hearings on health care and competition law and policy to be held April 9-11, 2003. These hearings will be held at the FTC Conference Center at 601 New Jersey Avenue, N.W...
The Federal Trade Commission and Department of Justice today released a detailed agenda for the sessions of their joint hearings on health care and competition law and policy to be held during April - May, 2003.
The second session of the Federal Trade Commission/Department of Justice joint hearings on health care and competition law and policy will begin on Wednesday, March 26 at 9:15 a.m. EST. The hearings will feature representatives of the FTC, the DOJ, the Department of Health & Human Services,...
The Federal Trade Commission (FTC) and the Department of Justice (DOJ) today released a detailed schedule for the sessions of their joint hearings on health care and competition law and policy to be held March 26-28, 2003. These hearings will be held at the FTC Conference Center at 601 New Jersey...
The Commission has received a petition from Solvay S.A.
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful...
The Federal Trade Commission today announced that Bristol-Myers Squibb Company (Bristol) - one of the world's largest drug makers - has settled charges that it engaged in a series of anticompetitive acts over the past decade to obstruct the entry of low-price generic competition for three of...
The Federal Trade Commission and Department of Justice today released a detailed agenda for the March/April session of their joint hearings on health care and competition law and policy along with an outline of the entirety of the hearings. The websites for the hearings are located at http://www....
Quest Diagnostics settled FTC charges that its proposed acquisition of Unilab Corporation would substantially increase concentration in the clinical laboratory testing services market by agreeing to divest clinical laboratory testing assets in Northern California to Laboratory...
In response to a request by a Dayton, Ohio, physicians' group, the Federal Trade Commission staff today issued an advisory opinion concerning the proposed formation and operation of a "healthcare advocacy group" of practicing physicians in the Dayton area. According to the letter requesting the...
On January 29, 2003 the Commission filed an amicus brief in the U.S. District Court for the Eastern District of Pennsylvania regarding the pending patent litigation between SmithKline Beecham (now known as GlaxoSmithKline or GSK) and Apotex Corporation, Apotex, Inc. and Torpharm Inc. (Apotex)...
Memorandum of the Federal Trade Commission, as amicus curiae, addressing the propriety of de-listing a patent from FDA's "Orange Book," as a remedy for patent invalidity. The brief explains that improperly-maintained Orange Book listings may serve as a barrier to competition, and...
The Federal Trade Commission and the Antitrust Division of the Department of Justice today announced that their joint hearings on "Health Care and Competition Law and Policy" will begin with three days of hearings on February 26-28, 2003. The hearings on February 26, 2003 will provide an...
Baxter settled Commission concerns stemming from its $316 million proposed acquisition of Wyeth Corporation's generic injectable drug business and agreed to divest several pharmaceutical products. The Commission charged that the acquisition would reduce competition in the manufacture...

Pages